Home Cart Sign in  
Chemical Structure| 1093070-14-4 Chemical Structure| 1093070-14-4

Structure of PLpro inhibitor
CAS No.: 1093070-14-4

Chemical Structure| 1093070-14-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 μM.

Synonyms: PLpro Inhibitor 6; KOM-70144; PLpro inhibitor, KOM70144

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PLpro inhibitor

CAS No. :1093070-14-4
Formula : C22H22N2O2
M.W : 346.42
SMILES Code : O=C(C1=CC(NC(C)=O)=CC=C1C)N[C@H](C)C2=C(C=CC=C3)C3=CC=C2
Synonyms :
PLpro Inhibitor 6; KOM-70144; PLpro inhibitor, KOM70144
MDL No. :MFCD12547684
InChI Key :KGPYBLOBHQLIET-OAHLLOKOSA-N
Pubchem ID :44235889

Safety of PLpro inhibitor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Vero E6 cells 25, 75, 100, 200, 300, 400 μM 24 hours To evaluate the antiviral potential of ATA, IC50 was 50 μM PMC9851725
HEK293T cells 10 μM 24 hours Evaluate the inhibitory effect of PLpro inhibitors on nsp1-nsp2 protein cleavage PMC8075810
Vero 0.41 µM 4 days Determine antiviral EC50 of WEHI-P4 by plaque assay, showing EC50 of 410 nM PMC11969009
Vero cells 10 µM 24 hours Evaluate the inhibitory effect of F0213 on SARS-CoV-2 NP antigen, results showed significant inhibition of viral replication. PMC8983325
HEK293T cells 20-80 μM 24 hours To assess whether GRL0617 can inhibit the in cyto deubiquitinating and deISGylating activity of SARS-CoV-2 PLpro. Results showed that GRL0617 partially recovered poly-ubiquitin-conjugates and ISG15-conjugates. PMC7817691
Vero E6 cells 0.17 to 3.18 μM 24 hours Evaluate antiviral activity, all four compounds showed strong antiviral effects PMC8052528
Differentiated normal human bronchial epithelial (dNHBE) cells 13.9 nM 3 days Evaluate the antiviral effect of PF-07957472 (4) in dNHBE cells PMC11364104
Vero E6 cells 100 μM 48 hours To evaluate the antiviral activity of GRL0617 against SARS-CoV-2. Results showed that 100 μM GRL0617 inhibited over 50% of viral replication. PMC7817691
Vero E6 cells 1.1 μM 48 hours Assessed the protective effect of compound 7 against SARS-CoV-2-induced cell death, with an EC50 of 1.1 μM, comparable to remdesivir PMC10044120
A549-hACE2 cells 2.5 μM (EC50) 48 hours Evaluate the antiviral activity of PLpro inhibitors in A549-hACE2 cells, results showed compound 10 exhibited broad-spectrum antiviral effects against SARS-CoV-2 original strain and variants PMC11345844
HACE2-HeLa cells 5 μM 48 hours Evaluate the inhibitory effect of PLpro inhibitors on SARS-CoV-2 replication PMC8075810
VeroE6-TMPRSS2 cells 2.2–4.8 µM 72 hours Evaluate the inhibitory effect of F0213 on SARS-CoV-2 variants, results showed dose-dependent inhibition against all variants. PMC8983325
Vero cells 11 μM and 33 μM 72 hours Assess the antiviral activity of PLpro inhibitors PMC7461020
LT-A549 8.352 μM 72 hours Evaluation of cytotoxicity of compound 5 on LT-A549 cells, showing CC50 of 45.775 μM. PMC10008816
Wi-38 10.356 μM 72 hours Evaluation of cytotoxicity of compound 5 on Wi-38 cells, showing CC50 of 51.781 μM. PMC10008816
Caco-2 cells 0.26 μM Evaluated the antiviral activity of compound 7 in human cells, with an EC90 of 0.26 μM against the USA-WA1/2020 strain PMC10044120
Vero E6 cells 68.2 μM Evaluate the antiviral effect of GRL0617 (1) in Vero E6 cells PMC11364104

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice SARS-CoV-2 P21 infection severe disease model Oral 100 mg/kg and 150 mg/kg Administered at 6, 24, and 48 hours post-infection Evaluate efficacy of WEHI-P8 in severe SARS-CoV-2 infection model, results showed both 100 mg/kg and 150 mg/kg doses significantly reduced viral load and alleviated lung inflammation PMC11969009
K18-hACE2 transgenic mice SARS-CoV-2 XBB.1 infection model Oral 25 mg/kg, 50 mg/kg, 100 mg/kg Treatment started 2 hours post-infection and lasted for 4 days Evaluate the antiviral efficacy of GZNL-P36 in SARS-CoV-2 infected Mice model, showing significantly improved survival and notable reductions in lung viral loads and lesions. PMC11585628
Mice BALB/c mice Oral 20, 50, 150 mg/kg Twice daily for 4 days Evaluate the antiviral effect of PF-07957472 in a Mice infection model PMC11364104
C57BL/6 mice SARS-CoV-2 MA10 infection model Intraperitoneal injection 10 mg/kg Twice daily for 2 days Evaluate the antiviral efficacy of PLpro inhibitors in Mice model, results showed compound 10 significantly reduced lung viral load PMC11345844
Syrian hamsters SARS-CoV-2 infection model Oral 15, 30, 45 mg/kg Once daily for 4 days To evaluate the in vivo antiviral potential of ATA, results showed reduction in viral load in throat swabs but no significant changes in lung tissues PMC9851725

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.43mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

References

 

Historical Records

Categories